A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to generate protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Maternal antibodies transferred through placenta protect newborns from day one
- Protection possible with two-week gap before premature birth
- Vaccination in third trimester still offers significant protection for infants
Strong evidence from current research
The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study undertaken in England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s conclusions have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The breadth of this investigation provides healthcare professionals and prospective parents with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s essential role in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology assessed practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents frequently observe their babies fighting for breath, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most newborns improve through clinical support, a limited though important number die from RSV complications each year, making vaccination as prevention a critical public health objective for safeguarding the youngest and most at-risk people in our communities.
- RSV triggers inflammation in lungs, causing serious respiratory problems in babies
- Approximately half of infants contract the virus in their first few months of life
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK infants require serious hospital care for RSV annually
- Small numbers of babies die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides nearly 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.
The messaging from health authorities remains clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to reach expectant mothers
- Inconsistencies across regions in immunisation take-up in different parts of England necessitate strategic intervention
- Regional health providers modifying schemes to suit local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness delivers real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this protective measure, the 80% reduction in admissions represents thousands of infants protected against critical disease. Parents no more face the upsetting situation of seeing their babies struggle for breath or struggle to eat, symptoms that define serious RSV disease. The vaccine has markedly changed the landscape of neonatal lung health, providing expectant mothers a active means to protect their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to severe brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to women in pregnancy navigating their late pregnancy, changing what was once an predictable seasonal threat into a controllable health concern.